ScholarWorks@Korea University: Song, Joon Young

Detailed Information

Song, Joon Young (송준영)

Graduate School (Department of Biomedical Sciences)

Research Area

Tel 구3005
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

COVID19:24||SARSCoV2:23||Influenza:11||Streptococcus pneumoniae:10||Safety:9||HIV:7||Immunogenicity:7||Korea:7||Vaccination:7||Vaccine:6||influenza:6||vaccine:5||Surveillance:4||Streptococcus agalactiae:4||pneumonia:4||Epidemiology:4||Mortality:4||Hospitalization:4||HIV/AIDS:4||Treatment:4||influenza vaccine:4||Pneumococcal conjugate vaccine:4||humoral immunity:3||Communicable diseases:3||elderly:3||Republic of Korea:3||Pneumococcal infections:3||Immunization:3||immunogenicity:3||Risk factors:3||influenza A virus:3||Effectiveness:3||cellular immunity:3||Pneumonia:3||Cohort studies:3||epidemiology:2||Hantavirus:2||Invasive aspergillosis:2||Voriconazole:2||Vaccines:2||Casecontrol study:2||immunoassay:2||Guideline:2||mortality:2||surveillance:2||Incidence:2||Adult:2||Acinetobacter baumannii:2||Skull base:2||Cervical lymphadenitis:2||Pathology:2||Adverse Events:2||COVID19 vaccines:2||Long COVID:2||Pregnancy:2||opsonophagocytic killing assay:2||antiviral agents:2||Seroprevalence:2||Adverse Event:2||vaccine effectiveness:2||Cohort study:2||Renal insufficiency:2||Influenza vaccine:2||prognosis:2||AIDSrelated opportunistic infections:2||Invasive pneumococcal disease:2||Human immunodeficiency virus:2||vaccination:2||COVID19 vaccination:2||DNA vaccine:2||Infection control:2||influenzalike illness:2||Hantaan virus:2||Quality control:1||Low birth weight:1||Obesity:1||Antiretroviral therapy highly active:1||lipoprotein:1||Hepatitis A:1||hospitalbased influenza morbidity and mortality (HIMM):1||H7N9 Virus:1||Hepatitis B virus:1||burden of disease:1||corticosteroid:1||influenza vaccines:1||Mucosal immunity:1||MERS:1||Hepatitis A virus:1||MF59 adjuvant:1||Serotyping:1||power Doppler sonography:1||Tuberculoma:1||Pneumococcal disease:1||Pneumococcus:1||Communityacquired pneumonia:1||Ageusia:1||Health personnel:1||matrix metalloproteinase13:1||mutation genetics:1||Humoral Immunity:1||antibody:1||mRNA1273 vaccine:1||Persistence of immune response:1||Thyroiditis:1||adult vaccines:1||Omicron:1||systemic review:1||nonAIDSdefining cancer:1||Vaccine effectiveness:1||Selection bias:1||safety:1||Data accuracy:1||Colorectal neoplasms:1||mucosal immunity:1||Liver Cirrhosis:1||Cellular immunity:1||severe dengue:1||cell culture techniques:1||Middle east respiratory syndrome coronavirus:1||Korea HIV:1||Health survey:1||screening tool:1||Opsonophagocytic killing assay:1||Pneumococcal infection:1||Bacterial Capsules:1||Severe Sepsis:1||sonography:1||Infected aortic aneurysm:1||inhalation:1||Middle East respiratory syndrome coronavirus:1||Hospital planning:1||atherosclerosis:1||CD8+ T cell:1||neutralizing activity:1||cytokine:1||vaccine preventable diseases:1||Influenza A virus:1||health service:1||Pneumococcal Conjugate Vaccine:1||Vaccine Efficacy:1||Monitoring:1||Halflife:1||Vaccine efficacy:1||Screening uptake:1||systems serology:1||effector function:1||acute kidney injury:1||therapeutic drug monitoring:1||Survival rates:1||Serosurveillance:1||Water wells:1||East Asia:1||Cohort Study:1||Campylobacter:1||H5N1:1||Broadspectrum protection:1||perception:1||HIVassociated neurocognitive disorder (HAND):1||Pneumococcal vaccines:1||Bacterial:1||neuraminidase:1||Kikuchi disease:1||Fever of unknown origin:1||Outbreaks:1||Control:1||Asymptomatic infection:1||Viral Load:1||Saliva:1||human immunodeficiency virus:1||adult vaccination:1||bivalent vaccine:1||reactogenicity:1||herpes zoster:1||MCP1:1||older Population:1||Chronic hepatitis B:1||antiviral therapy:1||Asian:1||20valent pneumococcal conjugate vaccine:1||obesity:1||Mycoplasma pneumoniae:1||vancomycin:1||under the curve:1||Ritonavir:1||Antiretroviral agents:1||Preterm birth:1||HIV Infection:1||live attenuated vaccine:1||maternal immunization:1||healthcare cost:1||Influenza A(H7N9) virus:1||hemophagocyticlymphohistiocytosis:1||human Influenza:1||clinical trial:1||influenza B virus:1||pep27 mutant:1||Quarantine:1||Cost of illness:1||health education:1||oseltamivir:1||emerging:1||PPSV23:1||CP: Immunology:1||standardized mortality ratio:1||functional markers:1||SARSCoV2 infection:1||T cell immune response:1||Suction mediated in vivo transfection:1||NKG2A:1||SARSCoV2 Omicron Variant:1||long COVID19:1||respiratory syncytial virus:1||Aged:1||Research design:1||Lopinavir:1||Public Health Response:1||Stomach neoplasms:1||rich repeat:1||History:1||Adherence:1||inactivated:1||Middle East respiratory syndrome:1||pregnancy:1||Personal protective equipment:1||Coronavirus:1||Antiviral:1||Polysaccharides:1||Septic Shock:1||Clostridium septicum:1||hospitalization:1||Salmonella typhimurium:1||host immune response:1||neutralizing antibody:1||HBsAg:1||mRNA Vaccine:1||postacute sequelae:1||Economic evaluation:1||NonNIP:1||ELISA:1||Gut Microbiome:1||Health screening:1||Propensity score matching:1||Smoking cessation:1||spike protein:1||PASC:1||Postacute COVID19 syndrome:1||Pandemics:1||survival:1||Antigenic determinants:1||group B Streptococcus:1||Influenzalike Illness:1||serine:1||latch:1||Hepatitis C virus:1||human:1||anxiety symptom:1||depressive symptom:1||epidemics:1||neuropsychological tests:1||risk factors:1||Pneumococcal vaccine:1||Chronic cardiovascular disease:1||Chronic respiratory disease:1||Gender:1||cervical lymphadenopathy:1||gray scale sonography:1||Colon cancer:1||Sequential vaccination:1||Social Distancing:1||p38 mitogenactivated protein kinase:1||live vaccine:1||quadrivalent vaccine:1||ORF3a:1||VPD:1||Nanoparticle vaccine:1||Metformin:1||Cardiovascular diseases:1||high dose quadrivalent influenza vaccine:1||Pneumococcal Pneumonia:1||Erythema nodosum:1||microbiota:1||adenovirus vectorbased vaccine:1||Therapeutic agents:1||hospital mortality:1||Hydroxychloroquine:1||CoInfection:1||Lgt:1||23valent pneumococcal vaccine:1||effectiveness:1||substitution:1||Human immunodeficiency virus:1||Disinfection:1||Biofilm:1||Antibacterial agents:1||Pneumococcal Infections:1||Chemoprophylaxis:1||Arthritis:1||Anosmia:1||PCV13:1||sequential vaccination:1||immunity:1||Autoimmune inflammatory rheumatic disease:1||Chlorhexidine:1||Coronavirus Disease 2019:1||radiation:1||RMET:1||attenuation:1||Adenovirus Vector:1||Cellular Immunity:1||memory cell:1||variants of concern:1||acquired immunodeficiency syndrome:1||averted outcomes:1||taxonomic markers:1||vaccines:1||booster:1||Recombinant protein vaccine:1||CommunityAcquired Pneumonia:1||Serotype:1||NK cells:1||Costeffectiveness:1||Longevity:1||RSV:1||AIDSdefining cancer:1||Influenza vaccines:1||Morbidity:1||intensive care units:1||Disparity:1||Data adjustment:1||Data quality:1||Hepatitis B Virus:1||National Cohort:1||Chemotherapy:1||pneumococcal vaccine:1||Sexually transmitted diseases:1||capsular polysaccharide:1||HIV infection:1||Coinfection:1||incidence:1||tickborne encephalitis:1||tickborne encephalitis virus:1||Bacteremia:1||Prevalence:1||dengue hemorrhagic fever:1||pandemic:1||Tuberculosis:1||HIVinfected patients:1||AIDS Cohort Study:1||drug resistance:1||Hemorrhagic fever with renal syndrome:1||pneumococcal vaccination:1||Risk Factor:1||Antiviral agents:1||Miliary tuberculosis:1||longevity:1||Closecontact transmission:1||ciclesonide:1||Disease outbreaks:1||communityacquired pneumonia:1||Seroepidemiology:1||group B streptococcus:1||GBS:1||MHC class I multimer:1||disease burden:1||gut microbiota:1||breakthrough infection:1||mRNA vaccines:1||IP10:1||costeffectiveness:1||Pneumococcal Polysaccharide Vaccine:1||metaanalysis:1||Clinical study:1||Booster shot:1||AIDS:1||Macrolides:1||Acquired immunodeficiency syndrome:1||Tobacco smoking:1||

RSS_1.0 RSS_2.0 ATOM_1.0

145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE